在经历OFF发作的帕金森病患者中,用或不使用抗emetic预治疗的apomorphine定位:一个修改的Delphi面板
Stuart H Isaacson1, Richard Dewey1, Robert A Hauser2
1Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.
Clinical parkinsonism & related disorders
|August 23, 2024
概括
在阿波莫尔芬治疗之前,通常不需要预先治疗. 专家们达成共识,阿波莫尔芬通常可以在没有使用抗药的情况下启动,从而简化了帕金森病患者的治疗.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在美国启动阿波莫芬治疗之前,预防性抗使用,特别是三甲胺,一直是标准的.
- 美国trimethobenzamide供应的耗尽,使人们对抗吐药预处理的必要性产生了不确定性.
研究的目的:
- 确定在哪些情况下可以在没有抗发药的预治疗的情况下启动阿波摩芬治疗的情况.
- 为了告知临床实践关于阿波莫芬启动协议.
主要方法:
- 一个经过修改的Delphi小组由9名美国运动障碍专家组成.
- 在192个患者场景中,小组成员评估了使用或不使用抗emetics的apomorphine启动的适当性.
- 共识被定义为强烈 (>75%) 或中度 (66%) 的同意.
主要成果:
- 强烈的共识 (97/192场景) 发现,在没有抗药的情况下,阿波莫芬启动是合适的.
- 观察到温和的共识 (29种情景) 和一些协议 (32种情景).
- 在没有使用抗药时,强烈建议基于剂量和反应的灵活定位.
结论:
- 专家们普遍认为,阿波莫尔芬可以在没有常规抗发前期治疗的情况下开处方.
- 这些发现提供了基于证据的建议,用于启动阿波莫尔芬治疗.
相关概念视频
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281


